Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-α agonist treatment

Mechanisms of Ageing and Development

Volumn 128, Issue 10, 2007, Pages 558-565

  Cree, Melanie G ^a   Newcomer, Bradley R ^b   Read, Laura K ^a   Sheffield Moore, Melinda ^a   Paddon Jones, Douglas ^a   Chinkes, David ^a   Aarsland, Asle ^a   Wolfe, Robert R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Aging; Insulin resistance; Intramuscular triglyceride; Liver fat; Plasma lipids

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID; FENOFIBRATE; GLUCOSE; INSULIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TRIACYLGLYCEROL;

ADIPOSE TISSUE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATTY ACID OXIDATION; FEMALE; FLATULENCE; GERIATRIC PATIENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SPACE; LIPID BLOOD LEVEL; LIVER; MALE; MUSCLE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; TRIACYLGLYCEROL BLOOD LEVEL; VOLUNTEER;

AGED; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; MUSCLE CELLS; PPAR ALPHA; PROCETOFEN; TRIGLYCERIDES;

ANIMALIA; EQUUS ASINUS;

EID: 34848827880     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2007.08.001     Document Type: Article

References (40)

1. Bajaj M., DeFronzo R., et al. Effects of PPAR-a/g therapy on glucose/lipid metabolism, hepatic fat and adiponectin in Type 2 diabets (T2DM). Diabetes 53 S2 (2004) A32
2. Boden G., Lebed B., et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50 7 (2001) 1612-1617
3. Boden G., Chen X., et al. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 93 6 (1994) 2438-2446
4. Charles M.A., Eschwege E., et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 40 9 (1997) 1101-1106
5. Chou C.J., Haluzik M., et al. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem. 277 27 (2002) 24484-24489
6. Cree M.G., Newcomer B.R., et al. PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial. Nutr. Metab. (Lond.) 4 (2007) 9
7. Cree M.G., Newcomer B.R., et al. Intramuscular and liver triglycerides are increased in the elderly. J. Clin. Endocrinol. Metab. 89 8 (2004) 3864-3871
8. Cree M.G., Qian T., et al. Fenofibrate improves insulin sensitivity and mitochondrial function in children with burn injury. Ann. Surg. 245 2 (2007) 214-221
9. Damci T., Tatliagac S., et al. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur. J. Intern. Med. 14 6 (2003) 357-360
10. Forcheron F., Cachefo A., et al. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 51 12 (2002) 3486-3491
11. Greco A.V., Mingrone G., et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 51 (2002) 144-151
12. Griffin M.E., Marcucci M.J., et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48 6 (1999) 1270-1274
13. Guerre-Millo M., Gervois P., et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275 22 (2000) 16638-16642
14. He J., Watkins S., et al. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 50 4 (2001) 817-823
15. Idzior-Walus B., Sieradzki J., et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur. J. Clin. Invest. 30 10 (2000) 871-878
16. Kanaya A.M., Fyr C.L., et al. Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule. Diab. Care 28 2 (2005) 404-408
17. Kelley D.E., and Simoneau J.A. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J. Clin. Invest. 94 6 (1994) 2349-2356
18. Klein S., and Romijn J. Obesity. In: Larsen P.R., Kronenberg H., Melmed S., and Polonsky K.S. (Eds). Williams Textbook of Endocrinology (2003), Saunders, Philadelphia, PA
19. Kobayashi M., Shigeta Y., et al. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diab. Care 11 6 (1988) 495-499
20. Levadoux E., Morio B., et al. Reduced whole-body fat oxidation in women and in the elderly. Int. J. Obes. Relat. Metab. Disord. 25 1 (2001) 39-44
21. Marchesini G., Brizi M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107 (1999) 450-455
22. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diab. Care 22 (1999) 1462-1470
23. Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin. Ther. 24 12 (2002) 2022-2050
24. Paolisso G., Tagliamonte M.R., et al. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia 41 10 (1998) 1127-1132
25. Paolisso G., Tataranni P.A., et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38 10 (1995) 1213-1217
26. Petersen K.F., Befroy D., et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300 5622 (2003) 1140-1142
27. Position-Statement. Standards of medical care in diabetes. Diab. Care 28 suppl. 1 (2005) S4-S36
28. Ramjattan B.R., Callaghan D.J., et al. Efficacy and tolerability of a suprabioavailable formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials. Clin. Ther. 24 7 (2002) 1105-1116
29. Rico-Sanz J., Thomas E.L., et al. Diversity in levels of intracellular total creatine and triglycerides in human skeletal muscles observed by 1H-MRS. J. Appl. Physiol. 87 6 (1999) 2068-2072
30. Rimbert V., Boirie Y., et al. Muscle fat oxidative capacity is not impaired by age but by physical inactivity: association with insulin sensitivity. FASEB J. 18 6 (2004) 737-739
31. Sane T., Knudsen P., et al. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism 44 5 (1995) 589-596
32. Shulman G.I. Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology (Bethesda) 19 (2004) 183-190
33. Su J.L., Simmons C.J., et al. Monitoring of PPAR alpha protein expression in human tissue by the use of PPAR alpha-specific MAbs. Hybridoma 17 1 (1998) 47-53
34. Tan C.E., Chew L.S., et al. Benefits of micronised fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. Atherosclerosis 154 2 (2001) 469-474
35. Taniguchi A., Fukushima M., et al. The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients. Metabolism 49 8 (2000) 1001-1005
36. van den Boogaart A., Van Hecke A., et al. MRUI: a graphical user interface for accurate routine MRS data analysis. Proceedings of the ESMRMB 13th Annual Meeting. Prague (1996) 318
37. Vega G.L., Cater N.B., et al. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin. Pharmacol. Ther. 74 3 (2003) 236-244
38. Wang Y., Michikawa Y., et al. Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. Proc. Natl. Acad. Sci. U.S.A. 98 7 (2001) 4022-4027
39. Wysocki J., Belowski D., et al. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int. J. Clin. Pharmacol. Ther. 42 4 (2004) 212-217
40. Yong Q.W., Thavintharan S., et al. The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome. Ann. Acad Med. Singapore 28 6 (1999) 778-782